TREATMENT OF PATIENTS WITH HIGH-RISK MYELODYSPLASTIC SYNDROMES RECEIVING AZACITIDINE WHO ARE ENROLLED IN AVIDA, A LONGITUDINAL PATIENT REGISTRY

被引：0
|
作者：
Grinblatt, L. [1 ]
Narang, X.
Malone, M. [2 ]
Sweet, A. [3 ]
Dunne, S. [3 ]
Sullivan, A. [3 ]
机构：
[1] NorthShore Univ HealthSyst, Evanston, IL USA
[2] Oncol Hematol Med Associates Cent Coast, San Luis Obispo, CA USA
[3] Celgene Corp, Summit, NJ USA
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2009年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1345
引用
收藏
页码：531 / 531
页数：1
相关论文
共 50 条
  • [41] Treatment of high-risk myelodysplastic syndromes with lymphoblastoid alphas interferon
    Petti, MC
    Latagliata, R
    Avvisati, G
    Spiriti, MAA
    Montefusco, E
    Spadea, A
    Mandelli, F
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 95 (02) : 364 - 367
  • [42] FAS Gene Expression Is Epigenetically Regulated and Predicts the Responsiveness to Azacitidine In High-Risk Myelodysplastic Syndromes
    Ettou, Sandrine
    Humbrecht, Catherine
    Benet, Blandine
    Kosmider, Olivier
    Droin, Nathalie
    Beyne-Rauzy, Odile
    Quesnel, Bruno
    Lacombe, Catherine
    Francois, Dreyfus
    Mayeux, Patrick
    Solary, Eric
    Fontenay, Michaela
    BLOOD, 2010, 116 (21) : 107 - 108
  • [43] Treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) in the elderly with azacitidine and gemtuzumab ozogamicin (GO)
    Nand, S.
    Godwin, J.
    Smith, S.
    Barton, K.
    Germano, E.
    Stiff, P.
    LEUKEMIA RESEARCH, 2007, 31 : S8 - S8
  • [44] Effect of azacitidine treatment on PI-PLC-beta1 expression inpatients affected by high-risk myelodysplastic syndromes
    Finelli, C.
    Follo, M. Y.
    Mongiorgi, S.
    Bosi, C.
    Clissa, C.
    Martinelli, G.
    Baccarani, M.
    Martelli, A. M.
    Cocco, L.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 160 - 160
  • [45] Rare lobular capillary hemangioma associated with azacitidine in high-risk myelodysplastic syndrome patient
    Grafanaki, Katerina
    Kourakli, Alexandra
    Skeparnias, Ilias
    Spiliopoulos, Theofanis
    Koumoundourou, Dimitra
    Bravou, Vasiliki
    Alexopoulos, Angelos
    Symeonidis, Argiris
    Georgiou, Sophia
    DERMATOLOGIC THERAPY, 2021, 34 (02)
  • [46] Identification of Predictive Factors for Overall Survival at Baseline and during Azacitidine Treatment in High-Risk Myelodysplastic Syndromes Treated in the Clinical Practice
    Scalzulli, Emilia
    Molica, Matteo
    Danilo, Alunni Fegatelli
    Rizzo, Lorenzo
    Latagliata, Roberto
    Foa, Robin
    Breccia, Massimo
    BLOOD, 2018, 132
  • [47] Low-dose melphalan for treatment of high-risk myelodysplastic syndromes
    Omoto, E
    Deguchi, S
    Takaba, S
    Kojima, K
    Yano, T
    Katayama, Y
    Sunami, K
    Takeuchi, M
    Kimura, F
    Harada, M
    Kimura, I
    LEUKEMIA, 1996, 10 (04) : 609 - 614
  • [48] Part 5: Myelodysplastic syndromes-Treatment of high-risk disease
    Meira Magalhaes, Silvia Maria
    Lopes Ferrari Chauffaille, Maria de Lourdes
    Rodrigues Pereira Velloso, Elvira Deolinda
    Buzzini, Renata
    Bernardo, Wanderley Marques
    HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2018, 40 (03) : 278 - 282
  • [49] Azacitidine for the treatment of lower risk myelodysplastic syndromes: final results from an Italian named patient program
    Musto, P.
    Maurillo, L.
    Spagnoli, A.
    D'Arco, A.
    Pollio, B.
    Candoni, A.
    Spiriti, A. Aloe
    Lunghi, M.
    Fili, C.
    Orciuolo, E.
    Venditti, A.
    Morabito, F.
    Mazza, P.
    Pastore, D.
    Santini, V.
    LEUKEMIA RESEARCH, 2009, 33 : S127 - S127
  • [50] The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update
    Silverman, L. R.
    Fenaux, P.
    Mufti, G. J.
    Santini, V.
    Hellstrom-Lindberg, E.
    Gattermann, N.
    Sanz, G.
    List, A. F.
    Gore, S. D.
    Seymour, J. F.
    Backstrom, J.
    McKenzie, D.
    Beach, C. L.
    ECANCERMEDICALSCIENCE, 2008, 2
12345